Hypokalemia: Difference between revisions

No edit summary
Line 4: Line 4:
*Central nervous system
*Central nervous system
**[[Weakness]]  
**[[Weakness]]  
**[[Cramps]]  
**[[myalgia|Cramps]]  
**[[Hyporeflexia]]
**Hyporeflexia  
*Gastrointestinal
*Gastrointestinal
**[[Ileus]]  
**[[Ileus]]  
Line 11: Line 11:
**[[Metabolic alkalosis]]
**[[Metabolic alkalosis]]
*Cardiovascular
*Cardiovascular
**PACs/PVCs  
**[[PACs]]/[[PVCs]]
**[[ACLS: Bradycardia|Bradycardia]] or atrial/junctional tachycardia  
**[[ACLS: Bradycardia|Bradycardia]] or [[atrial tachycardia|atrial]]/[[junctional tachycardia]]
**[[AV block]]  
**[[AV block]]  
**[[Tachycardia (wide)|Ventricular tachycardia]], [[Adult pulseless arrest|Ventricular fibrillation]]
**[[Tachycardia (wide)|Ventricular tachycardia]], [[Adult pulseless arrest|Ventricular fibrillation]]
Line 21: Line 21:
*Alkalosis (each 0.10 rise in pH causes 0.5 decrease)
*Alkalosis (each 0.10 rise in pH causes 0.5 decrease)
*[[Insulin]]
*[[Insulin]]
*B-agonist
*[[Beta agonists]]
*[[Hypokalemic periodic paralysis]]
*[[Hypokalemic periodic paralysis]]


===Decreased intake===
===Decreased intake===
*Special diets or those low in potassium
*Special diets or those low in potassium
*Chronic alcohol abuse
*Chronic [[alcohol Abuse|alcohol abuse]]
 
===Increased loss===
===Increased loss===
*GI
*GI
**Vomiting, diarrhea, fistula
**[[Vomiting]], [[diarrhea]], fistula
*Renal
*Renal
**Diuretics
**[[Diuretics]]
**Hyperaldo
**Hyperaldosteronism
**Exercise
**Exercise
**[[Hypercalcemia]]
**[[Hypercalcemia]]
**[[Hypomagnesemia]]
**[[Hypomagnesemia]]
===Drugs===
===Drugs===
*[[Penicillins]]
*[[Penicillins]]
*[[Lithium toxicity|Lithium]]
*[[Lithium toxicity|Lithium]]
*L-dopa
*L-dopa
*[[Theophylline]], methylxanthines
*[[Theophylline]], methylxanthines (e.g. [[caffeine]]
*[[Insulin]]
*[[Insulin]]
*Barium
*Barium
Line 70: Line 72:
**Must be given in dilute solutions at slow rate (10meq/hour) to minimize side effects and cardiac toxicity
**Must be given in dilute solutions at slow rate (10meq/hour) to minimize side effects and cardiac toxicity
**Generally should not give more than 40mEq via IV
**Generally should not give more than 40mEq via IV
**Side effects: Local tissue burning, phelbitis, sclerosis
**Side effects: Local tissue burning, phlebitis, sclerosis
*Also treat [[Hypomagnesemia]] if present
*Also treat [[Hypomagnesemia]] if present
*Re-check ECG after treatment <ref>Slovis, Corey. "Electrolyte Emergencies". Presentation.</ref>
*Re-check ECG after treatment <ref>Slovis, Corey. "Electrolyte Emergencies". Presentation.</ref>

Revision as of 16:10, 29 September 2019

Background

Clinical Features

Differential Diagnosis

Differential diagnosis of hypokalemia

Intracellular Shift

Decreased intake

Increased loss

Drugs

Evaluation

ECG Hypokalemia.jpg

Management

  • Potassium repletion (PO or IV)
    • Every 10mEq KCl → serum K ↑ ~0.1mEq/L
    • PO preferred (if symptomatic or level is <2.5, both oral and IV should be given)
  • Oral potassium
    • Inexpensive and rapidly absorbed
    • KCl tablet (elixir form available but has poor taste)
    • K-Dur (extended release tablet) is large and may be difficult to swallow
  • Intravenous potassium
    • Must be given in dilute solutions at slow rate (10meq/hour) to minimize side effects and cardiac toxicity
    • Generally should not give more than 40mEq via IV
    • Side effects: Local tissue burning, phlebitis, sclerosis
  • Also treat Hypomagnesemia if present
  • Re-check ECG after treatment [1]
  • Hypokalemia in acute or recent myocardial infarction places patients at much higher risk for ventricular fibrillation[2]
    • Previous studies and many professional organizations recommend maintaining K between 4.0 - 5.0 mEq/L in MI patients
    • However, more recent studies suggest 3.5 - 4.5 mEq/L results in the lowest mortality

Disposition

  • Based on underlying cause

See Also

External Links

References

  1. Slovis, Corey. "Electrolyte Emergencies". Presentation.
  2. Goyal A et al. Serum Potassium Levels and Mortality in Acute Myocardial Infarction. JAMA. 2012;307(2):157-164.